A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis

Title
A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis
Authors
Keywords
Clinical trial, Wnt pathway, Patient-reported outcomes, CLK2, DYRK1A, Knee pain
Journal
OSTEOARTHRITIS AND CARTILAGE
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-02-15
DOI
10.1016/j.joca.2021.02.004

Ask authors/readers for more resources

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now